Aficamten (1) – Myqorzo®
Hypertrophic obstructive cardiomyopathy
Characteristics
| Start date | 01.06.2026 |
|---|---|
| Resolution | 19.11.2026 – active procedure |
| INN | Aficamten |
| Brand name | Myqorzo® |
| Pharm. company | Cytokinetics Germany GmbH |
| G-BA Procedure ID | D-1321 |
| Therapeutic area | Cardiovascular diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions